0001564590-19-035081.txt : 20190920 0001564590-19-035081.hdr.sgml : 20190920 20190920090040 ACCESSION NUMBER: 0001564590-19-035081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20190920 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190920 DATE AS OF CHANGE: 20190920 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FIBROGEN INC CENTRAL INDEX KEY: 0000921299 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36740 FILM NUMBER: 191102732 BUSINESS ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-978-1200 MAIL ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 fgen-8k_20190920.htm 8-K fgen-8k_20190920.htm
false FIBROGEN INC 0000921299 0000921299 2019-09-20 2019-09-20

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 20, 2019

 

FibroGen, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36740

 

77-0357827

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

FibroGen, Inc.

409 Illinois Street

San Francisco, CA 94158

(Address of principal executive offices, including zip code)

(415) 978-1200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

FGEN

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

 

 

 

 

 

Item 8.01

Other Events

On September 20, 2019, FibroGen, Inc., together with its collaboration partner Astellas Pharma Inc., announced that the Ministry of Health, Labour and Welfare in Japan has approved Evrenzo® (generic name: roxadustat) for the treatment of anemia associated with chronic kidney disease in dialysis patients.

A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

 

 

Exhibits

 

 

 

Exhibit No.

  

Description

 

 

99.1

 

 

104

  

Press Release titled “Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients” dated September 20, 2019

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

FIBROGEN, INC.

 

 

 

Dated: September 20, 2019

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

/s/ Michael Lowenstein

 

 

 

 

 

 

Michael Lowenstein

 

 

 

 

 

 

Chief Legal Officer

 

 EX-99.1 2 fgen-ex991_6.htm EX-99.1 fgen-ex991_6.htm

 

Exhibit 99.1

 

 

 

 

Press Release

 

Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

 

SAN FRANCISCO and Tokyo, September 20, 2019- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo® (generic name: roxadustat; tradename Evrenzo® in Japan) for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients.

 

Roxadustat is a first-in-class orally administered inhibitor of hypoxia-inducible factor (HIF) prolylhydroxylase that corrects anemia by a mechanism of action that is different from that of erythropoiesis-stimulating agents (ESAs). As a HIF-PH inhibitor, roxadustat activates a response that occurs naturally when the body responds to reduced oxygen levels in the blood. The response activated by roxadustat involves the regulation of multiple, complementary processes to promote erythropoiesis and increase the blood’s oxygen-carrying capacity.

 

“Evrenzo® is a valuable new treatment option for dialysis patients with CKD anemia,” said Bernhardt G. Zeiher, M.D., Chief Medical Officer, Astellas. “Astellas is committed to improving the health of people worldwide and expanding treatment options, especially within the dialysis community where there is high-unmet need. We are delighted to bring this important new treatment option to both patients suffering from, and healthcare professionals treating, this debilitating condition.”

 

CKD anemia can severely worsen the outcomes of kidney disease, increasing the rate of progression to renal failure1 and the likelihood of cardiovascular complications.2 It also significantly reduces patients’ quality of life and their cognitive ability.3 Reaching and maintaining target hemoglobin levels can present challenges and roxadustat provides an alternative therapeutic option.

 

“We appreciate the commitment and focus of our partner Astellas as we work together to bring a new therapy to CKD anemia patients on dialysis in Japan,” said K. Peony Yu, M.D., Chief Medical Officer, FibroGen. “With this approval in Japan, NDA approval in China, and EU MAA and U.S. NDA preparations underway, we are another step closer to our goal of addressing the significant unmet medical need of patients living with anemia associated with CKD, worldwide.”

 

1

 

 

The approval is based on four Phase 3 studies conducted in CKD anemia patients on dialysis in Japan.4,5,6,7 The studies demonstrated that roxadustat was effective at raising hemoglobin and that it was well-tolerated. This marks the first approval for roxadustat through the Astellas and FibroGen collaboration.

 

Product Information

 

PRODUCT NAME

 

Evrenzo® Tablets 20mg

Evrenzo® Tablets 50mg

Evrenzo® Tablets 100mg

GENERAL NAME

Roxadustat

INDICATIONS

Renal anemia in patients on dialysis

DOSAGE AND ADMINISTRATION

Patients not on erythropoiesis-stimulating agent treatment.

For adults, the usual dosage is 50mg, the starting dose, as roxadustat orally administered three times weekly. The dosage thereafter should be adjusted according to the patient’s condition; however, the maximum dose should not exceed 3.0mg/kg.

 

Patients switching from erythropoiesis-stimulating agents.

For adults, the usual dosage is 70 or 100mg, the starting dose, as roxadustat orally administered three times weekly. The dosage thereafter should be adjusted according to the patient’s condition; however, the maximum dose should not exceed 3.0mg/kg.

APPROVAL DATE

 

September 20, 2019

 

About Chronic Kidney Disease (CKD) and Anemia
CKD is a progressive loss of kidney function caused by damage to the kidneys resulting from conditions such as hypertension, diabetes, or immune-regulated inflammatory conditions.8 Worldwide, more than 1 in 10 people are living with CKD.9 In Japan, specifically, the prevalence of CKD has increased significantly over time.10 Although CKD can occur at any age, it becomes more common in aging populations, and the prevalence is increasing. CKD is a critical worldwide healthcare issue that represents a large and growing unmet medical need.

 

Anemia is a common early complication of CKD,11 affecting approximately 20% of patients with CKD.12 It results from the failing kidneys’ diminished ability to produce erythropoietin that stimulates red blood cell production from the bone marrow, and is associated with significant morbidity and mortality in dialysis and non-dialysis populations, increasing in both prevalence and severity as kidney disease worsens.13 CKD anemia increases the risk of adverse cardiovascular events, worsens renal outcomes and negatively impacts patients’ quality of life.14,15 In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large and growing unmet medical need.

 

About Roxadustat
In addition to receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, roxadustat is approved in China for treatment of anemia associated with CKD in both dialysis-dependent and non-dialysis-dependent CKD patients. U.S. NDA and EU MAA preparation is underway. Roxadustat is also in Phase 3

2

 

 

clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes. For information about roxadustat studies, please visit www.clinicaltrials.gov at: https://clinicaltrials.gov/ct2/results?term=roxadustat&Search=Search.

 

Astellas and FibroGen are collaborating on the development of roxadustat for the potential treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, and other markets.

 

About FibroGen
FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH) activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is approved by the National Medical Products Administration (NMPA) in China, and by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.

 

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit https://www.astellas.com/en.

 

FibroGen Forward-looking Statements

This release contains forward-looking statements regarding FibroGen strategy, future plans and prospects, including statements regarding the development of the company’s product candidates, the potential safety and efficacy profile of our product candidates, and our clinical and regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and our quarterly report on 10-Q for the fiscal quarter ended June 30, 2019 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

 

3

 

 

Astellas Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

 

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

 

###

 

 

Contacts for inquiries or additional information:

 

Karen L. Bergman

FibroGen, Inc.
Investor Relations and Corporate Communications
+1 (415) 978-1433
ir@fibrogen.com

 

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

 

References:

 

 

1 

Mohanram A, Zhang Z, Shahinfar S,ET AL. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004 Sep;66(3):1131-8.

2 

Weiner DE , Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004 Aug;44(2):198-206.

3 

Eriksson D et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrology. 2016;17:97.

4 

1517-CL-0302: Announced on a press release issued on October 31, 2017. Available at: https://www.astellas.com/jp/en/news?type=date&tab=date&year=2017&month=10

5 

1517-CL-0308: Announced on slide no. 29 of presentation material at Astellas FY2017 business announcement on April 26, 2018. Available at: https://sw4503.swcms.net/en/ir-library/business-results/inframe/main/00/teaserItems1/00/linkList/02/link/4q2018_pre_en.pdf

6 

1517-CL-0312: Announced on slide no. 29 of presentation material at Astellas FY2017 business announcement on April 26, 2018. Available at: https://sw4503.swcms.net/en/ir-library/business-results/inframe/main/00/teaserItems1/00/linkList/02/link/4q2018_pre_en.pdf

7 

1517-CL-0307: Announced on a press release issued on May 31. Available at: https://www.astellas.com/jp/en/news/11951

8 

Ojo, A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Transactions of the American Clinical and Climatological Association. 2014, No. 125, p. 229-246.

9 

The Global Kidney Health Atlas. International Society of Nephrology (ISN). Available at: https://www.kidneycareuk.org/news-and-campaigns/news/estimated-1-10-people-worldwide-have-chronic-kidney-disease/. Last accessed August 2019.

10 

Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. Nephrol Dial Transplant. 2010, Aug, vol. 25, no.8, 2557-2564.

11 

McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr.Med.Res.Opin. 2004;20:1501–1510.

12 

Dmitrieva O, De Lusignan S, Macdougall, IC, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrology. 2013:25;14:24.

13 

KDOQINational Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 [Suppl 3]: S11–S145, 2006.

14 

Eriksson D et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrology. 2016;17:97.

15 

KDOQINational Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 [Suppl 3]: S11–S145, 2006.

4

 

 GRAPHIC 3 g34gh13buyut000001.jpg GRAPHIC begin 644 g34gh13buyut000001.jpg M_]C_X 02D9)1@ ! 0$ W #< #_X01817AI9@ 34T *@ @ #P#^ 0 M ! $ 0 ! $]P$! 0 ! !2P$" , # P@$# M , ! 4 $& , ! ( $1 0 !O R $5 , ! , M $6 0 ! P$7 0 !O "A $: 4 ! $0 $; 4 ! M $2 $< , ! $ $H , ! ( $] , ! ( M" ( @ ( NP 6X (A "U X< 0Z $[0 !: 93 M '!@ ![D BA )? "E\ LV ,&0 #/X W? .RP #^0 M !$S 2Q %%8 !88 7T0 &<< !O3 =[ ("@ "*D DN M)Z\ "LE NT@ ,B8 #5U XN0 ._T #_# !$#@ 2, $WK !1 M< 5)4 %>Y !<,@ 83, &6E !J

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end GRAPHIC 4 g34gh13buyut000002.jpg GRAPHIC begin 644 g34gh13buyut000002.jpg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end EX-101.SCH 5 fgen-20190920.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 fgen-20190920_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 7 fgen-20190920_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fgen-8k_20190920.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "fgen-8k_20190920.htm" ] }, "labelLink": { "local": [ "fgen-20190920_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "fgen-20190920_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "fgen-20190920.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fgen", "nsuri": "http://www.fibrogen.com/20190920", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "fgen-8k_20190920.htm", "contextRef": "C_0000921299_20190920_20190920", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "fgen-8k_20190920.htm", "contextRef": "C_0000921299_20190920_20190920", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "fgen_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.fibrogen.com/20190920", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports fgen-8k_20190920.htm fgen-20190920.xsd fgen-20190920_lab.xml fgen-20190920_pre.xml fgen-ex991_6.htm http://xbrl.sec.gov/dei/2019-01-31 true false XML 14 fgen-8k_20190920_htm.xml IDEA: XBRL DOCUMENT 0000921299 2019-09-20 2019-09-20 false FIBROGEN INC 0000921299 8-K 2019-09-20 DE 001-36740 77-0357827 409 Illinois Street San Francisco CA 94158 415 978-1200 false false false false Common Stock, $0.01 par value FGEN NASDAQ false XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information
Sep. 20, 2019
Document And Entity Information [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 20, 2019
Entity Registrant Name FIBROGEN INC
Entity Central Index Key 0000921299
Entity Emerging Growth Company false
Entity File Number 001-36740
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 77-0357827
Entity Address, Address Line One 409 Illinois Street
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code 415
Local Phone Number 978-1200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, $0.01 par value
Trading Symbol FGEN
Name of each exchange on which registered NASDAQ

EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end ZIP 17 0001564590-19-035081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-035081-xbrl.zip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